INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
INSMED Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$95.29−0.98 (-1.02%)
Close on Oct 19, 2026
- Market cap
- $20.71B
- P/E (TTM)
- –
- Dividend yield
- –
INSMED Inc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| ARIKAYCE external R&D expenses | $433.77M | $363.71M | $305.21M | – | – | – | 71.5% | +19.3% |
| BRINSUPRI | $172.66M | $0 | $0 | – | – | – | 28.5% | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| United States | $452.95M | $254.80M | $224.20M | $185.99M | $159.51M | $157.52M | 74.7% | +77.8% |
| International | $153.47M | $108.91M | $81.01M | – | – | – | 25.3% | +40.9% |
| Japan | – | $87.70M | $65.73M | $56.51M | $16.01M | $0 | – | – |
| Europe and rest of world | – | $21.21M | $15.28M | $2.86M | $12.95M | $6.89M | – | – |
From the segment and revenue-disaggregation notes of Insmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.